Personalized Search
Displaying 1 - 20 of 122
-
Dr. Mikkael Sekeres describes why patients should request a second opinion about their bone marrow failure disease or blood cancer. He also shares his own perspective about asking for a second opinion, recommending that patients do select this option.Podcast Episode last updated September 21, 2023.Node ID (debugging only): 10335
-
BOSTON, May 25, 2022 – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have...Article last updated May 30, 2023.Node ID (debugging only): 9972
-
Dr. Tiffany Tanaka from the University of California, San Diego explains the development of High-Risk MDS into AML. She talks about new diagnostic and treatment regimens for these patients.Podcast Episode last updated November 2, 2022.Node ID (debugging only): 8811
-
H. Joachim Deeg, MD, is a board certified oncologist at Seattle Cancer Care Alliance, a University of Washington Professor of Medicine and Oncology and a researcher at Fred Hutchinson Cancer Research Center.Podcast Episode last updated November 2, 2022.Node ID (debugging only): 8253
-
Kat hears patients ask: "I have this bone marrow failure problem ... how is this going to affect me and loved ones? What does this mean for my life?" Discover how Kat helps walk patients through diagnosis, treatment, and survivorship.Podcast Episode last updated November 2, 2022.Node ID (debugging only): 8211
-
From a sunny, lively retirement to MDS then AML? That was Shirley's life! After treatment in a Clinical Trial, she is in remission, still playing the accordion! This is her story.Podcast Episode last updated November 2, 2022.Node ID (debugging only): 8210
-
Nancy has worked with hundreds of patients in her career, guiding patients through decision-making and treatment. Discover her best advice for bone marrow failure patients and caregivers in this podcast.Podcast Episode last updated November 2, 2022.Node ID (debugging only): 8187
-
This is the first episode of our new podcast. Leigh Clark, Patient Educator, describes the bone marrow failure journey and how AAMDSIF can help!Podcast Episode last updated November 2, 2022.Node ID (debugging only): 8157
-
In evidence-based guidelines issued by the American Society of Hematology and published in the Aug. 11 issue of Blood Advances, recommendations are presented for the management of newly diagnosed acute myeloid leukemia (AML) in older adults. Mikkael A. Sekeres, M.D., from the Taussig Cancer Center at the Cleveland Clinic, and colleagues developed evidence-based guidelines to support patients,...Article last updated April 6, 2022.Node ID (debugging only): 9116
-
The FDA has granted a fast track designation for aspacytarabine as treatment for acute myeloid leukemia in adults aged 75 years or older who have comorbidities that preclude the utilization of intensive induction chemotherapy. The FDA has granted a fast track designation for aspacytarabine (BST-236) as treatment for acute myeloid leukemia (AML) in adults aged 75 years or older who have...Article last updated April 6, 2022.Node ID (debugging only): 9095
-
VIDEO Description: Treatment Approaches in AML: Key Testing for Personalized Care from Patient Empowerment Network on Vimeo. When it comes to Acute Myeloid Leukemia (AML), genetic testing (or biomarker testing) is essential in helping to determine the best treatment approach for YOU. In this program, AML expert, Dr. Naval Daver reviews key decision-making factors, current AML treatments and...Article last updated April 6, 2022.Node ID (debugging only): 9143
-
Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area. Significant disparities were found between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia (AML...Article last updated April 6, 2022.Node ID (debugging only): 9260
-
Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival in patients with acute myeloid leukemia. John C. Byrd, MD Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival (OS...Article last updated April 6, 2022.Node ID (debugging only): 9199
-
A precision medicine treatment approach that incorporates genomic data into treatment decisions appears to be feasible in older patients with untreated acute myeloid leukemia (AML), according to a study published in Nature Medicine. Investigators also found that delaying treatment until mutational data were available did not seem to increase the risk of early death or adversely impact overall...Article last updated April 6, 2022.Node ID (debugging only): 9292
-
Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut, discusses updated results from an ongoing retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in patients with relapsed/refractory FLT3-positive acute myeloid leukemia (AML). Dr Zeidan presented these results at the virtual 62nd American Society of...Article last updated April 6, 2022.Node ID (debugging only): 9314
-
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) – called NPM1 – that could help predict survival and improve treatment response for patients whose leukemic cells bear the mutation. In research published Feb. 16, in Nature Communications, a team led by Princess Margaret Cancer Centre...Article last updated April 6, 2022.Node ID (debugging only): 9523
-
Meningioma-1 (MN1) is a protein whose overexpression has been linked to acute myeloid leukemia (AML) and brain tumors, and 70% to 80% of AML patients with high overexpression of MN1 die within two years. Yet the mechanism by which MN1 causes these diseases has largely remained a mystery. “Looking at the sequence, the protein has no obvious structure,” said Kathrin M. Bernt, MD, a pediatric...Article last updated April 6, 2022.Node ID (debugging only): 9614
-
Link above leads to podcast recording.Article last updated April 6, 2022.Node ID (debugging only): 9843
-
TP53-mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival. Across TP53-altered MDS and AML, standard therapies for wild-type disease have been of minimal benefit, but a wave of investigational agents currently in...Article last updated April 6, 2022.Node ID (debugging only): 9277
-
December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia. GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), according to data from initial dose cohorts of a phase 1...Article last updated April 6, 2022.Node ID (debugging only): 9264